{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:32:46Z","timestamp":1791347566710,"version":"4.3.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T00:00:00Z","timestamp":1283385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T00:00:00Z","timestamp":1283385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1038\/leu.2010.185","type":"journal-article","created":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T09:43:13Z","timestamp":1283420593000},"page":"1719-1724","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":231,"title":["Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR"],"prefix":"10.1038","volume":"24","author":[{"given":"D M","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Branford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J F","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A P","family":"Schwarer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P A","family":"Bartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Slader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Field","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R J","family":"Filshie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A K","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A P","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J V","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T P","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,2]]},"reference":[{"key":"BFleu2010185_CR1","doi-asserted-by":"publisher","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","volume":"13","author":"S Branford","year":"2007","unstructured":"Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007; 13: 7080\u20137085.","journal-title":"Clin Cancer Res"},{"key":"BFleu2010185_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58\u201360.","journal-title":"Blood"},{"key":"BFleu2010185_CR3","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.V112.11.402.402","volume":"112","author":"DM Ross","year":"2008","unstructured":"Ross DM, Grigg A, Schwarer A, Arthur C, Loftus K, Mills AK et al. The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR, and any relapses occur early. Blood 2008; 112: 402\u2013403, Abstract no. 1102.","journal-title":"Blood"},{"key":"BFleu2010185_CR4","doi-asserted-by":"crossref","unstructured":"Mahon FX, Rea D, Guilhot F, Legros L, Guilhot J, Aton E et al. Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation: Interim analysis of the STIM trial. J Clin Oncol 2009; 27, Abstract no. 7084.","DOI":"10.1200\/jco.2009.27.15_suppl.7084"},{"key":"BFleu2010185_CR5","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362","volume":"92","author":"S Bose","year":"1998","unstructured":"Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV . The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362\u20133367.","journal-title":"Blood"},{"key":"BFleu2010185_CR6","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V86.8.3118.3118","volume":"86","author":"C Biernaux","year":"1995","unstructured":"Biernaux C, Loos M, Sels A, Huez G, Stryckmans P . Detection of major BCR-ABL gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118\u20133122.","journal-title":"Blood"},{"key":"BFleu2010185_CR7","first-page":"69","volume":"125","author":"S Branford","year":"2006","unstructured":"Branford S, Hughes T . Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Methods Mol Med 2006; 125: 69\u201392.","journal-title":"Methods Mol Med"},{"key":"BFleu2010185_CR8","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1038\/sj.leu.2403157","volume":"17","author":"MC Muller","year":"2003","unstructured":"Muller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha\/ara-C. Leukemia 2003; 17: 2392\u20132400.","journal-title":"Leukemia"},{"key":"BFleu2010185_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1365-2141.1993.tb03026.x","volume":"84","author":"NC Cross","year":"1993","unstructured":"Cross NC, Hughes TP, Feng L, O\u2019Shea P, Bungey J, Marks DI et al. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol 1993; 84: 67\u201374.","journal-title":"Br J Haematol"},{"key":"BFleu2010185_CR10","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1182\/blood-2005-08-3320","volume":"107","author":"J Kaeda","year":"2006","unstructured":"Kaeda J, O\u2019Shea D, Szydlo RM, Olavarria E, Dazzi F, Marin D et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 2006; 107: 4171\u20134176.","journal-title":"Blood"},{"key":"BFleu2010185_CR11","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1373\/clinchem.2008.105916","volume":"54","author":"DM Ross","year":"2008","unstructured":"Ross DM, Watkins DB, Hughes TP, Branford S . Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease. Clin Chem 2008; 54: 1568\u20131571.","journal-title":"Clin Chem"},{"key":"BFleu2010185_CR12","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of \u2032real-time\u2032 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318\u20132357.","journal-title":"Leukemia"},{"key":"BFleu2010185_CR13","unstructured":"Score J, Calasanz MJ, Pane F, Ottmann O, Grand FH, Cross NCP . Analysis of t(9;22) breakpoints indicates that p210 and p190 BCR-ABL are formed by distinct mechanisms. Haematologica 2007; 92, Abstract no. 2."},{"key":"BFleu2010185_CR14","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267\u20131270.","journal-title":"Nature"},{"key":"BFleu2010185_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428190500407996","volume":"47","author":"J Goldman","year":"2006","unstructured":"Goldman J, Gordon M . Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma 2006; 47: 1\u20137.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2010185_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","volume":"101","author":"A Burchert","year":"2003","unstructured":"Burchert A, Wolfl S, Schmidt M, Brendel C, Denecke B, Cai D et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2003; 101: 259\u2013264.","journal-title":"Blood"},{"key":"BFleu2010185_CR17","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/79526","volume":"6","author":"JJ Molldrem","year":"2000","unstructured":"Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018\u20131023.","journal-title":"Nat Med"},{"key":"BFleu2010185_CR18","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1182\/blood-2007-12-128397","volume":"111","author":"CI Chen","year":"2008","unstructured":"Chen CI, Maecker HT, Lee PP . Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 2008; 111: 5342\u20135349.","journal-title":"Blood"},{"key":"BFleu2010185_CR19","doi-asserted-by":"crossref","unstructured":"Sobrinho-Simoes M, Wilczek V, Score J, Cross NC, Apperley JF, Melo JV . In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood, e-pub ahead of print 12 May 2010; DOI 10.1182\/blood-2009-11-255109.","DOI":"10.1182\/blood-2009-11-255109"},{"key":"BFleu2010185_CR20","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/sj.leu.2403752","volume":"19","author":"T Lange","year":"2005","unstructured":"Lange T, Bumm T, Mueller M, Otto S, Al-Ali HK, Grommisch L et al. Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation. Leukemia 2005; 19: 1262\u20131265.","journal-title":"Leukemia"},{"key":"BFleu2010185_CR21","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/nm1487","volume":"12","author":"I Roeder","year":"2006","unstructured":"Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M . Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006; 12: 1181\u20131184.","journal-title":"Nat Med"},{"key":"BFleu2010185_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"VH van der Velden","year":"2007","unstructured":"van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604\u2013611.","journal-title":"Leukemia"},{"key":"BFleu2010185_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/gcc.20568","volume":"47","author":"E Mattarucchi","year":"2008","unstructured":"Mattarucchi E, Guerini V, Rambaldi A, Campiotti L, Venco A, Pasquali F et al. Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia. Genes Chromosomes Cancer 2008; 47: 625\u2013632.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFleu2010185_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1365-2141.1995.tb03392.x","volume":"90","author":"JG Zhang","year":"1995","unstructured":"Zhang JG, Goldman JM, Cross NC . Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR. Br J Haematol 1995; 90: 138\u2013146.","journal-title":"Br J Haematol"},{"key":"BFleu2010185_CR25","first-page":"4146","volume":"5","author":"CF Waller","year":"1999","unstructured":"Waller CF, Dennebaum G, Feldmann C, Lange W . Long-template DNA polymerase chain reaction for the detection of the BCR\/ABL translocation in patients with chronic myelogenous leukemia. Clin Cancer Res 1999; 5: 4146\u20134151.","journal-title":"Clin Cancer Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2010185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2010185","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2010185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T13:31:40Z","timestamp":1648733500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2010185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,2]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["BFleu2010185"],"URL":"https:\/\/doi.org\/10.1038\/leu.2010.185","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,2]]},"assertion":[{"value":"19 April 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DMR was a PhD Scholar of the Leukaemia Foundation of Australia. DMR, SB, JFS, APS, CA, AKM, APG and TPH have received honoraria from Novartis Oncology. CS is an employee of Novartis Oncology. PAB, CF, PD, RJF and JVM have no conflict of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}